Is ADIL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ADIL. It does not provide personalized investment advice.

ADIL (Adial Pharmaceuticals, Inc) Stock Analysis - Financials

Adial Pharmaceuticals, Inc (ADIL) is a publicly traded Healthcare sector company. As of August 28, 2026, ADIL trades at $5.59 with a market cap of $16.69M and a P/E ratio of -0.47. ADIL moved +0.00% today. Year to date, ADIL is -6.39%; over the trailing twelve months it is -42.39%. Its 52-week range spans $1.31 to $32.50. Analyst consensus is buy with an average price target of $8.50. Rallies surfaces ADIL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ADIL's key financials?

ADIL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ADIL recently traded at $5.59. Market cap is $16.69M. P/E ratio is -0.47. Revenue is $0.

ADIL Key Metrics

Key financial metrics for ADIL
Metric	Value
Price	$5.59
Market Cap	$16.69M
P/E Ratio	-0.47
EPS	$-11.93
Dividend Yield	0.00%
52-Week High	$32.50
52-Week Low	$1.31
Volume	35.76K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-7.98M
Gross Margin	0.00%

ADIL Analyst Consensus

2 analysts cover ADIL: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.50.

Common questions about ADIL

What are ADIL's key financials?: ADIL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ADIL recently traded at $5.59. Market cap is $16.69M. P/E ratio is -0.47. Revenue is $0.
Is ADIL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ADIL. It does not provide personalized investment advice.